Results 101 to 110 of about 48,006 (264)

Association of inferior vena cava filter placement for venous thromboembolic disease and a contraindication to anticoagulation with 30-day mortality [PDF]

, 2018
Importance: Despite the absence of data from randomized clinical trials, professional societies recommend inferior vena cava (IVC) filters for patients with venous thromboembolic disease (VTE) and a contraindication to anticoagulation therapy.
Brown, David L, Novak, Eric, Saeed, Mohammed J, Turner, Tyson E   +3 more
core   +1 more source

Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels

Haemophilia, EarlyView.
ABSTRACT Introduction Valoctocogene roxaparvovec, an adeno‐associated virus (AAV)‐based gene therapy, enables endogenous factor VIII (FVIII) expression in patients with severe hemophilia A without the need for regular FVIII infusions. Long‐term follow‐up assesses durability, safety, and immune‐related challenges following gene therapy.
Kerstin Herbst, Behnaz Pezeshkpoor, Claudia Klein, Thilo Albert, Philipp Lutz, Christian Strassburg, Ulrich Spengler, Georg Goldmann, Johannes Oldenburg   +8 more
wiley   +1 more source

Treatment of Haemophilia A Without Inhibitors: Real‐World Treatment Patterns and Clinical Outcomes in the US

Haemophilia, EarlyView.
ABSTRACT Introduction Despite available prophylactic therapies for haemophilia A, breakthrough bleeding and consequent pain and joint damage still occur. Aim To provide insights into the unmet treatment needs of people with moderate‐to‐severe haemophilia A in the US.
Allison P. Wheeler, Lauren E. Amos, Shveta Gupta, Sylvie Bozzi, Gandarvaka Miles, Kalyani Hawaldar, Andrew Wilson, Gillian Hanson, Emily Cibelli, Amanda Wilson, Siddhi Umarje, Anne‐Laure Tardy, Jennifer Dumont, Graham Neill, Alix Arnaud   +14 more
wiley   +1 more source

Evaluation of the Clinical Status of Patients with Inherited Bleeding Disorders in Diyala-Iraq

Diyala Journal of Medicine, 2019
Background: Inherited bleeding disorders are rare diseases that are both complicated and expensive to manage, they are classified into: coagulation factor disorders, vessel wall defect and platelet disorders.
Imad Ahmed Lateef
doaj   +2 more sources

Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies [PDF]

, 2000
Acquired hemophilia, caused by autoantibodies against coagulation factor VIII, is usually treated with steroids, cyclophosphamide, intravenous gammaglobulins and sporadically other drugs.
Baele, Gaston, Derom, Eric, Petrovic, Mirko   +2 more
core  

Treatment of hemophilia B: focus on recombinant factor IX

Biologics: Targets & Therapy, 2013
Massimo Franchini, Francesco Frattini, Silvia Crestani, Cinzia Sissa, Carlo BonfantiDepartment of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, ItalyAbstract: Hemophilia B is a recessive X-linked bleeding disorder characterized by ...
Franchini M, Frattini F, Crestani S, Sissa C, Bonfanti C   +4 more
doaj  

Performing Large‐Scale Genetic Analysis in the Bleeding Disorders Community

Haemophilia, EarlyView.
ABSTRACT Inherited bleeding disorders encompass a diverse group of conditions caused by genetic defects affecting coagulation factors, fibrinogen, von Willebrand factor, or platelet function. Despite major advances in quantitative and functional laboratory assays, a substantial diagnostic gap remains, particularly in patients with mild or atypical ...
Anna R. Blankstein, Sterre P. E. Willems, Saskia E. M. Schols, Rosanna Asselta, Gillian Lowe, Neil V. Morgan, Paula D. James   +6 more
wiley   +1 more source

Persons with high Hemophilia Joint Health Scores have reduced functional range of motion during simulated sports activities

Research and Practice in Thrombosis and Haemostasis
Background: Joint bleeds for persons with hemophilia are characteristic and can lead to hemophilic arthropathy, primarily in the ankles, knees, and elbows.
Danielle N. Siegel, Caden Robertson, Joanna Roybal, Joseph Mah, Laura Singer-Fox, Dianne Thornhill, Niamh Mah, Sharon Funk, Marilyn Manco-Johnson, James Carollo, Brecca M.M. Gaffney, Beth B. Warren   +11 more
doaj   +1 more source

Hemophilia B [PDF]

, 2020
openaire   +2 more sources

Assessing the Impact of the 2021 VWD Guidelines on the Diagnosis/Management of Low VWF Patients

Haemophilia, EarlyView.
ABSTRACT Introduction The 2021 ASH/ISTH/NHF/WFH VWD diagnosis guidelines recommend Type 1 VWD diagnoses for patients with (a) VWF <0.30 IU/mL or (b) ‘Low VWF’ 0.30–0.50 IU/mL with the presence of abnormal bleeding. This recommendation recategorizes ‘Low VWF’ patients with abnormal bleeding into Type 1 VWD.
Michael Dong, Joanna Larson, Sepideh Saroukhani, Miguel Escobar, Lakshmi Srivaths   +4 more
wiley   +1 more source